Based on a descriptive analysis of five studies, this paper found no significant correlation between the RFC1 G80A polymorphism and HD-MTX adverse reactions in osteosarcoma patients which is similar to the findings of a systematic evaluation in patients with hematological malignancies. Here, RFC1 is linked to osteosarcoma.